Navigation Links
New York State Approves the Quest Diagnostics ColoVantage™ Colorectal Cancer Blood Test
Date:3/17/2011

MADISON, N.J., March 17, 2011 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading cancer diagnostics company, today announced that its ColoVantage test has been approved by New York State's Department of Health for testing on samples of patients in the state. It is believed to be the first molecular colorectal cancer detection method that employs a venal blood specimen to be approved by the state.  

"ColoVantage is a convenient, noninvasive option for the millions of patients 50 years of age and older who resist testing by recommended screening methods," said Jon R. Cohen, M.D., senior vice president and chief medical officer, Quest Diagnostics. "As a technique that patients may actually use, ColoVantage is arguably the first practical testing option to promote meaningful cancer evaluation among this large underserved population. It is fitting that March, colorectal cancer awareness month, marks the date our test met New York's rigorous regulatory criteria."

Men and women at average risk for colorectal cancer should be screened beginning at age 50, according to the American Cancer Society, but only about half of this population nationally is up-to-date on screening. Some patients regard recommended tests, such as colonoscopy, flexible sigmoidoscopy and fecal occult blood tests (FOBTs), as invasive or unpleasant, and refuse or delay testing.

ColoVantage is designed to aid in the detection of colorectal cancer in patients who resist testing by guideline-recommended screening methods. Unlike other colorectal cancer tests, ColoVantage does not require dietary restrictions or special preparations and testing can be added to routine blood work. As with any noncolonoscopy test, a positive test result should be followed up by colonoscopy.

The test detects methylated DNA of the Septin9 gene from a specimen of blood taken from a patient's arm. The Septin9 biomarker has shown consistently high performance in colorectal cancer detection in several case-control studies. The biomarker was licensed to Quest Diagnostics by its owner Epigenomics AG (Frankfurt, Prime Standard: ECX), a cancer molecular diagnostics company, in 2008.

In a clinical validation study, ColoVantage correctly identified colorectal cancer in 70 percent of samples of people diagnosed with the cancer. It also correctly detected the absence of colorectal cancer in about 89 percent of samples tested.

"ColoVantage cannot replace colonoscopy, and it has yet to be validated for colon cancer screening," said Jay G. Wohlgemuth, M.D., vice president, science and innovation, Quest Diagnostics. "But the test's ability to detect this cancer may persuade nonadherent screening-eligible individuals who receive a positive result to undergo colonoscopy or other evaluation."

Quest Diagnostics was the first laboratory in the United States to offer a molecular test employing blood taken from a patient's arm for aiding in the detection of colorectal cancer when it released ColoVantage in December 2009. New York is the only U.S. state with an independent regulatory review process for laboratory developed tests, which are also regulated at the federal level. With the approval, Quest Diagnostics can offer ColoVantage in New York as well as in all other U.S. states.

Colorectal cancer is the third most common cancer in men and women in the U.S., with more than 51,000 deaths expected this year, according to estimates from ACS.

About Quest Diagnostics and its Commitment to Colorectal Cancer Testing Quest Diagnostics is the world's leading provider of diagnostic testing, information and services that patients and doctors need to make better healthcare decisions. The company offers the broadest access to diagnostic testing services through its network of laboratories and patient service centers, and provides interpretive consultation through its extensive medical and scientific staff. Quest Diagnostics is a pioneer in developing innovative diagnostic tests and advanced healthcare information technology solutions that help improve patient care.

Quest Diagnostics is a leader in colorectal cancer diagnostics, offering a full spectrum of testing that ranges from predisposition analysis to monitoring for disease recurrence. In addition to ColoVantage, the company offers the InSure(R) FIT, an FDA-cleared FOBT test for use in screening for sources of lower gastrointestinal bleeding based on laboratory testing of a stool-based specimen. The company also offers EGFR Pathway mutation testing to help predict patient response to certain therapies for metastatic colorectal cancer, genetic testing to aid in evaluating a patient's inherited predisposition to develop colorectal cancer, and anatomic pathology biopsy testing to confirm a diagnosis.

Additional company information is available at www.QuestDiagnostics.com. For information on ColoVantage, visit www.ColoVantage.com. Contacts:Wendy Bost (Media): 973-520-2800Kathleen Valentine (Investors): 973-520-2900
'/>"/>

SOURCE Quest Diagnostics Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Medicsight Receives Brazilian State Food and Drug Administration Approval for ColonCAD Software
2. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
3. Baxter Announces Licensing Agreement for Innocolls Gentamicin Surgical Implant in the United States
4. States First Single Incision Robotic Kidney Removal Performed at Henry Ford Hospital
5. InVitria Further Strengthens Sales Team with Promotion of Brandy Sargent to Account Manager - Western United States
6. Revolutionary New In-Office EVOLVE(R) Laser Prostate Treatment Available Throughout Western Oregon
7. Orange Coast Urology Offers Advanced In-Office Patient EVOLVE(R) Laser Prostate Treatment
8. Department of Justice Provides States With Funding for Testing in Postconviction Cases
9. NC State engineers discover nanoparticles can break on through
10. JD Technologies, LLC Selected by FCT Ingenieurkeramik GmbH to Represent Their High Performance Ceramic Expertise In the United States
11. Exposure to Agent Orange linked to prostate cancer in Vietnam veterans
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... ... April 28, 2016 , ... Morris Midwest ( http://www.morrismidwest.com ), ... manufacturers at its Maple Grove, Minnesota technical center, May 11-12. The event ... Almost 20 leading suppliers of tooling, accessories, software and other related technology ...
(Date:4/27/2016)... ... April 27, 2016 , ... The Pittcon Organizing Committee ... Chuck has been a volunteer member of Committee since 1987. Since then, he ... of directors and treasurer and was chairman for both the program and exposition committees. ...
(Date:4/27/2016)... and RESEARCH TRIANGLE PARK, N.C. , ... UTHR ) announced today that Martine Rothblatt ... Therapeutics will provide an overview and update on the ... Annual Health Care Conference. The presentation will ... a.m. Eastern Time, and can be accessed via a ...
(Date:4/27/2016)... ... April 27, 2016 , ... PathSensors, Inc., a leading environmental ... Lamka will assist PathSensors in expanding the use of the company’s CANARY® technology ... test platform for the detection of harmful pathogens, including a number of bacteria, ...
Breaking Biology Technology:
(Date:3/31/2016)... , March 31, 2016  Genomics firm Nabsys ... founding CEO, Barrett Bready , M.D., who returned ... of the original technical leadership team, including Chief Technology ... of Product Development, Steve Nurnberg and Vice President of ... to the company. Dr. Bready served as ...
(Date:3/23/2016)... 2016 Einzigartige ... und Stimmerkennung mit Passwörtern     ... MESG ), ein führender Anbieter digitaler Kommunikationsdienste, ... SpeechPro zusammenarbeitet, um erstmals dessen Biometrietechnologie einzusetzen. ... Möglichkeit angeboten, im Rahmen mobiler Apps neben ...
(Date:3/22/2016)... , PROVO and ... Newborn Screening Ontario (NSO), which operates the highest sample ... molecular testing, and Tute Genomics and UNIConnect, leaders in ... respectively, today announced the launch of a project to ... (NGS) testing panel. NSO has been ...
Breaking Biology News(10 mins):